Itacitinib

Drug Profile

Itacitinib

Alternative Names: INCB-039110; INCB-039110-adipate; INCB39110

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Hodgkin's disease; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 07 Sep 2017 Massachusetts General Hospital, Incyte Pharmaceuticals and Sundry plan a phase I trial for Malignant melanoma and Solid tumours (Combination therapy) in USA (NCT03272464)
  • 10 Aug 2017 Chemical structure information added
  • 08 Jun 2017 Phase-III clinical trials in Graft-versus-host disease (Combination therapy, Treatment-naive) in United Kingdom, Turkey, Taiwan, Switzerland, Spain, Singapore, Portugal, Poland, New Zealand, Netherlands, South Korea, Italy, Israel, Hungary, Greece, Germany, France, Czech Republic, Canada, Belgium, Austria, Australia (PO) (NCT03139604)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top